医药行业的人才迁徙曲线,正在划出行业发展的拐点。“金九银十”之际,本土药企掀起一轮高管密集更迭潮,不约而同把橄榄枝抛向拥有跨国履历的“新掌门”。仅10月9日,关键任命“四连发”:礼来中国抗肿瘤事业部前副总裁尹航空降恒瑞,执掌肿瘤事业部;复星医药前董事长吴以芳转场康桥资本;艾伯维中国区前总经理欧思朗签约绿叶制药。隔日,10月10日,刚宣布退休的阿斯利康中国前副总裁朱理琍闪电复出,出任医朵云总经理。...
Source Link医药行业的人才迁徙曲线,正在划出行业发展的拐点。“金九银十”之际,本土药企掀起一轮高管密集更迭潮,不约而同把橄榄枝抛向拥有跨国履历的“新掌门”。仅10月9日,关键任命“四连发”:礼来中国抗肿瘤事业部前副总裁尹航空降恒瑞,执掌肿瘤事业部;复星医药前董事长吴以芳转场康桥资本;艾伯维中国区前总经理欧思朗签约绿叶制药。隔日,10月10日,刚宣布退休的阿斯利康中国前副总裁朱理琍闪电复出,出任医朵云总经理。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.